for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
  Medtech Insight
   Full-text available via subscription Subscription journal
   ISSN (Print) 1876-8008
   Published by Informa plc Homepage  [14 journals]
  • Neuromodulation 2015: Innovation Expands Opportunities In Chronic Pain
    • Abstract: In the market for neuromodulation devices, the largest opportunity is in the treatment of chronic pain, a condition that affects more than 1.5 billion people worldwide. Innovation is driving growth in this sector as companies develop next-generation neuromodulation technologies designed to improve outcomes, and resolve some of the problems with existing devices; these technologies will significantly expand the treatable population, and will allow companies both large and small to capture market share based on device efficacy and the strength of clinical evidence.
      PubDate: Tue, 28 Apr 2015 00:05:17 -040
  • Hearing Aid Industry Poised For Growth
    • Abstract: The aging baby boomer population is driving linear growth in the multibillion-dollar hearing aid market, which increased 4.76% in 2014, with 3.1 million units sold in the US alone according to the Hearing Industries Association. To drive further growth and capture market share, hearing aid manufacturers have been catering to boomers, and developing new high-tech hearing aids that are more like wearable health care technology, with improved performance and wireless connectivity to electronic devices.
      PubDate: Tue, 28 Apr 2015 00:05:10 -040
  • Companion Diagnostics Come Of Age
    • Abstract: The US companion diagnostics sector is predicted to grow from $1.6 billion to $6.2 billion between 2015 and 2021, a CAGR of 25.3%, outpacing the IVD market growth fivefold. This rapid growth will be driven by the development of new targeted pharmaceutical products and moves by the FDA to quickly approve new treatments and diagnostics together.
      PubDate: Tue, 28 Apr 2015 00:05:00 -040
  • Novel Devices Penetrate Migraine Headache Market
    • Abstract: Several new device-based therapies are emerging designed to fill the treatment gap for migraine suffers who do not respond to traditional migraine therapies. These novel treatments include a headband-like device designed to stimulate the trigeminal nerve and an image-guided intranasal interventional treatment.
      PubDate: Tue, 28 Apr 2015 00:00:50 -040
  • Tattoo-Based Biosensor To Track Fitness, Monitor Glucose
    • Abstract: Start-up Electrozyme is developing a noninvasive, wearable, tattoo-based biosensor platform for fitness tracking and glucose monitoring that is unlike any device on the market. The company is planning to launch its first product in 2016 and is working with key strategics that make their own wearables to distribute the biosensors under an OEM model.
      PubDate: Tue, 28 Apr 2015 00:00:45 -040
  • Potential Breakthrough Treatment For Enlarged Prostate
    • Abstract: A potential breakthrough treatment for patients with an enlarged prostate is attracting attention as studies begin to show a new interventional technique could be a very effective alternative to surgery. A minimally invasive procedure known as prostate artery embolization was one of the main subjects of an interventional radiology conference, where results of a study were recently released.
      PubDate: Tue, 28 Apr 2015 00:00:40 -040
  • Companion Diagnostics Oncology Deals, 2013-Q1 2015
    • Abstract: A comprehensive list of compation diagnostics deals in oncology signed January 2013 through March 2014.
      PubDate: Tue, 28 Apr 2015 00:00:34 -040
  • Velano Vascular: Vascular Access Via Peripheral IV Catheters
    • Abstract: Velano Vascular Inc. aims to spare hospitalized patients the pain of numerous needle blood draws. It is commercializing a single-use, disposable vascular-access device that resembles a syringe and interacts with an existing peripheral intravenous catheter that has already been inserted in the patient’s hand or arm.
      PubDate: Tue, 28 Apr 2015 00:00:29 -040
  • 3DBiopsy: Real-Time 3D Prostate Biopsy Technology
    • Abstract: 3DBiopsy LLC thinks its technology could significantly improve a physician’s ability to diagnose and treat patients suspected of having prostate cancer. It has developed a complete biopsy system that utilizes the start-up’s proprietary software to transform ultrasound or MRI imaging into 3D models of the prostate and give physicians a more accurate guide.
      PubDate: Tue, 28 Apr 2015 00:00:20 -040
  • Cerevast Therapeutics’ Ultrasonic Stroke Treatment Gains Momentum
    • Abstract: Cerevast Therapeutics is gaining momentum as the company raises new funds and advances enrollment in its pivotal Phase III clinical trial evaluating its Clotbust ER, an ultrasonic head-frame that delivers acoustic energy to the brain to enhance clot dissolution in acute ischemic stroke patients who receive intravenous tPA.
      PubDate: Tue, 28 Apr 2015 00:00:15 -040
  • Medtech Execs On The Move, April 2015
    • Abstract: Recent executive-level company changes and promotions in the medical device and diagnostics industries.
      PubDate: Tue, 28 Apr 2015 00:00:09 -040
  • Medical Device Deals Update, April 2015
    • Abstract: Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced March–April 2015.
      PubDate: Tue, 28 Apr 2015 00:00:00 -040
  • Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For
    • Abstract: Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
      PubDate: Fri, 27 Mar 2015 00:05:40 -040
  • New Injectables For Knee OA Fuel US Joint Fluid Market
    • Abstract: Although several factors have recently slowed growth in the US market for joint fluid replacement, it remains large and vastly underpenetrated with an estimated 15.8 million knee osteoarthritis patients who are hoping to delay the need for a total knee arthroplasty. With a growing number of products in the pipeline and increasing adoption of new single-injection products, the US joint fluid market is projected to increase from approximately $924.4 million in 2015 to more than $1.07 billion by 2019, a CAGR of 4%.
      PubDate: Fri, 27 Mar 2015 00:05:28 -040
  • Targeting The Tongue: Helius Medical’s Unique Approach To
           Neuromodulation Tested In Trials
    • Abstract: Neuromodulation start-up Helius Medical Technologies is employing a simpler, more primal connection to send potentially therapeutic signals to the brain – the tongue. The company is entering pivotal clinical trials to test the technology in select patients with traumatic balance disorder and traumatic brain injury, and evaluating the device for use in patients with multiple sclerosis.
      PubDate: Fri, 27 Mar 2015 00:05:18 -040
  • AF Ablation Procedures Driving CRM Market Expansion
    • Abstract: Cardiac rhythm management device sales in the US are projected to grow at a compound annual rate of 2.9%, increasing to an estimated $8.2 billion in the year 2019. Two of the fastest growing sectors of the market, electrophysiology and ablation devices, will be driven by a 10% to 20% growth in the number of patients treated for atrial fibrillation.
      PubDate: Fri, 27 Mar 2015 00:05:01 -040
  • Intact Vascular: Optimizing Balloon Angioplasty For Peripheral Arterial
    • Abstract: An alternative to traditional stents to treat peripheral arterial disease, Intact Vascular Inc.’s Tack Endovascular System uses multiple, small nitinol implants to reduce metal exposure when treating peripheral arterial disease. The Tack system minimizes the metal that is left in the artery compared with a stent and also decreases the vessel inflammation associated with stents.
      PubDate: Fri, 27 Mar 2015 00:00:49 -040
  • Major Players Keep Remote Patient Monitoring Moving Forward
    • Abstract: Medtronic and Roche have made important moves in the remote monitoring market with new partnerships designed to enhance their places in telemedicine, which continues to be an important point of emphasis for providers. Meanwhile, AliveCor, a young company with groundbreaking cardiology technology for the smartphone, has reached an important milestone in Europe.
      PubDate: Fri, 27 Mar 2015 00:00:38 -040
  • Medtronic’s VenaSeal Closure System Receives
           FDA Approval For Treating Chronic Venous Disease
    • Abstract: Adding to its product portfolio for treating superficial venous reflux, Medtronic has now received US approval for a more minimally invasive device, the VenaSeal closure system, which uses adhesive injections to seal the diseased vein in select patients with chronic venous insufficiency. Superficial venous reflux can lead to symptomatic varicose veins.
      PubDate: Fri, 27 Mar 2015 00:00:32 -040
  • ECR 2015: Radiology Trends To Watch
    • Abstract: Five important trends emerged at the European Congress of Radiology (ECR) meeting held in Vienna in March that could shape the future of radiology. Trends to watch include the growing importance of quantitative imaging, Big Data management, the rebirth of ultrasound, miniaturization, as well as a trend toward more cost-effective, “mid-range” scanners.
      PubDate: Fri, 27 Mar 2015 00:00:27 -040
  • Medical Device Deals Update, March 2015
    • Abstract: Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced February-March 2015.
      PubDate: Fri, 27 Mar 2015 00:00:19 -040
  • 3Scan: 3D Models Of Tissue Biology
    • Abstract: Pathology workflow hasn’t changed much since the field began some 100 years ago – tissue is sectioned with a microtome, mounted to a glass slide, and placed into a microscope – but the process could dramatically change for the better, thanks to the digital Knife Edge Scanning Microscope from 3Scan Inc. What has traditionally been a manual and qualitative process, KESM facilitates with high throughput, quantified image analysis and computation of tissue sliced as thin as 1 micron.
      PubDate: Fri, 27 Mar 2015 00:00:11 -040
  • Medtech Execs On The Move, March 2015
    • Abstract: Recent executive-level company changes and promotions in the medical device and diagnostics industries.
      PubDate: Fri, 27 Mar 2015 00:00:01 -040
  • US Heart Valve Treatments Market Fueled By New Transcatheter Valves
    • Abstract: The US heart valve treatments market will reach $1.7 billion by 2019, driven by advances in percutaneous heart valve repair and replacement products and a growing number of competitors entering this space. With US sales of transcatheter aortic valve replacement systems set to almost triple in the next several years, the combined US market for products to treat heart valve disorders is expected to grow at a CAGR of 7.7%.
      PubDate: Fri, 27 Feb 2015 00:05:23 -050
  • Companies Forge Ahead With New Devices, Studies, And Funding For
           Treatment-Resistant Hypertension
    • Abstract: With Medtronic planning to submit an IDE application to the FDA soon to conduct a new US trial of its renal denervation technology, companies and investors alike remain optimistic about finding an effective device-based therapy for treatment-resistant hypertension. Two smaller players in this space – Rox Medical and Verve Medical – are also forging ahead, due to recently published encouraging study results for Rox’s stent-like implant, Coupler, and a nearly $2 million Series B1 round to fund further clinical trials of Verve’s Phoenix RF energy device.
      PubDate: Fri, 27 Feb 2015 00:05:18 -050
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015